[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584490":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":26,"locations":34,"responsibleParty":71,"collaborators":10,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Aristotle University Of Thessaloniki","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observation group",null,"Patients hospitalized due to acute coronary syndromes (STEMI, NSTEMI)",[13],"Diagnostic Test: Observation group",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Christodoulos E. Papadopoulos, PhD","Aristotle University of Thessaloniki, Greece","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":23},"Georgios Zormpas, MD",[27,32],{"name":21,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","2313312343","+30","chrpapado@gmail.com",{"name":25,"role":28,"phone":29,"phoneExt":30,"email":33},"sparky.zorb@gmail.com",[35],{"facility":36,"status":37,"city":38,"state":10,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Ippokratio General Hospital","RECRUITING","Thessaloniki","54642","Greece","GR",{"type":43,"coordinates":44},"Point",[45,46],22.93493,40.64072,{"lat":46,"lon":45},[49,50,51,52,55,57,59,61,63,65,67,69],{"name":25,"role":28,"phone":29,"phoneExt":30,"email":33},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":25,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":53,"role":54,"phone":10,"phoneExt":10,"email":10},"Georgios Kassimis, PhD","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":10,"phoneExt":10,"email":10},"Michael Doumas, PhD",{"name":58,"role":54,"phone":10,"phoneExt":10,"email":10},"Aristi Boulmpou, MSc",{"name":60,"role":54,"phone":10,"phoneExt":10,"email":10},"Nikolaos Fragakis, PhD",{"name":62,"role":54,"phone":10,"phoneExt":10,"email":10},"Vassilios Vassilikos, PhD",{"name":64,"role":54,"phone":10,"phoneExt":10,"email":10},"Theodoros Karapantsios, PhD",{"name":66,"role":54,"phone":10,"phoneExt":10,"email":10},"Sotiris Evgenidis, PhD",{"name":68,"role":54,"phone":10,"phoneExt":10,"email":10},"Konstantinos Zacharias, PhD",{"name":70,"role":54,"phone":10,"phoneExt":10,"email":10},"Nikoleta Chatzipapa, MSc",{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584490","a-prospective-single-center-observational-study-aiming-to-assess-the-predictive-role-of-flow-mediated-dilatation-in-acute-coronary-syndromes-combined-with-echocardiographic-and-biochemical-indices-100584490",false,"NCT06890013","A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices","Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)","FLARE-ACS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)\n3. Capability of providing written informed consent\n4. Patients able to comply with the follow-up schedule of the study\n\nExclusion Criteria:\n\n1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction\n2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome\n3. Patients with congenital heart disease\n4. Age \\> 85 years\n5. Patients with end stage chronic kidney disease\n6. Patients with active malignancy or autoimmune diseases which limit their survival\n7. Patients with expected survival \\\u003C 1 year due to other reasons\n8. Suboptimal echocardiographic windows\n9. Inability to provide written consent\n10. Inability to comply with the follow-up schedule of the study\n11. Pregnancy\n12. Use of intravenous drugs","ALL","18 Years","85 Years",{"count":85,"type":86},100,"ESTIMATED","OBSERVATIONAL","A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.",[90,91,92],"Acute Coronary Syndromes","Flow Mediated Dilation","Endothelial Function (FMD)",[94,95,96,97],"acute coronary syndrome","endothelial dysfunction","biomarker","flow mediated dilatation","2026-02-27",{"date":100,"type":101},"2026-03-02","ACTUAL",{"date":103,"type":101},"2024-06-01",{"date":105,"type":86},"2026-11-01",{"name":5,"class":6},1]